Novartis Animal Health has issued the following statement concerning the supply of acepromazine (ACP) injectable in the UK:
"Recent upgrades to Novartis Animal Health’s manufacturing plant in the UK have resulted in the site becoming a worldwide centre of excellence for the production of bulk liquids. This upgrade has had an impact on the manufacture of ACP 2mg/ml and 10mg/ml injectable products, which will no longer be produced in the UK.
From January 2011, Novartis Animal Health will no longer be able to supply ACP Injection 2mg/ml or ACP Injection 10mg/ml to wholesalers. However, it is not Novartis’ intention to discontinue the supply of acepromazine injectable; in order to ensure consistency of supply to the UK market the company will be importing the Vetoquinol French product Calmivet.
Calmivet is a monovalent acepromazine injection licensed for use in dogs, cats and horses, available as a 5mg/ml injection, 50ml vial.
In order to obtain Calmivet from wholesalers, veterinarians will need to apply for a free of charge Special Import Certificate from the VMD. This can be completed on line at www.vmd.gov.uk.
It is anticipated that this situation will continue for at least the first 6 months of 2011, until an alternative manufacturing site is established. As soon as we have more information on the timelines this will be communicated.
A full communication including a prep room reminder poster and Calmivet product leaflet has been mailed to all UK practices.
Vetoquinol UK are not responsible for the distribution or technical support of this product, so any queries should be directed to Novartis Animal Health UK on 01276 694402.
The production and supply of ACP Tablets 10mg remains unaffected."
Bayer Animal Health has launched a next generation fluoroquinolone antimicrobial - Veraflox (pradofloxacin) - for the treatment of bacterial infections in cats and dogs.
Bayer Animal Health's marketing manager Dr Markus Edingloh said: "Veraflox, with its molecular compound pradofloxacin, developed exclusively for veterinary medicine, marks a major leap forward in veterinary antibiotic therapy and patient care.
"Veraflox has an enhanced spectrum of antimicrobial activity which encompasses Gram-positive and anaerobic bacteria. In addition, Veraflox has demonstrated high levels of bactericidal activity against target pathogens including activity against dormant bacteria typically found in chronic infections."
For cats, an oral suspension is available in which a fine-grained ion exchange agent binds to the antibiotic, apparently allowing it to pass the cat's taste buds undetected. Bayer says this innovation has been adopted specifically to ensure the product is palatable to cats, and help ensure owner compliance. The oral suspension comes with a syringe with both millilitre and gramme graduations, to help ensure accurate dosing.
Veraflox oral suspension is indicated for the treatment of upper respiratory tract infections, wound infections and abscesses. The 15mg tablet is also licensed in cats for treating upper respiratory tract infections.
Bayer says that in addition to its other indications, Veraflox is also very effective at combatting anaerobic bacteria that play a major role in aggressive bone destruction in canine periodontal disease, and it is the first fluoroquinolone to be licensed in dogs for the adjunctive treatment of severe infections of the gingiva and periodontal tissues.
In addition to its dental claim for dogs, Veraflox is also indicated for the treatment of wound infections, superficial and deep pyoderma, and acute urinary tract infections. It is given to dogs as a once-daily flavoured tablet.
Dr Edingloh added: "The unique chemistry and way in which Veraflox works gives it superior antibacterial activity compared with existing fluoroquinolones. In addition, during field studies, Veraflox was shown to be superior to other leading antibiotic products.
"Pradofloxacin has been proven to have a wide spectrum of activity, outstanding antibacterial activity, and an excellent safety margin. Its pharmacokinetic features ensure this active ingredient can rapidly get to the site of infection, at which it has a great impact on the pathogen population.
"One of the most common reasons for treatment failure where antibiotics are concerned is lack of owner compliance. The availability of Veraflox as an oral suspension with a graded syringe for cats, will enable more accurate dosing, far easier administration and so ensure higher cure rates.
"The launch of Veraflox is the first major advance in its class, since the introduction of Baytril, the first veterinary fluoroquinolone, over 20 years ago. Veraflox provides vets with more predictability, reliability and peace of mind, especially in difficult to treat infections."
For further information on Veraflox, please contact your Bayer representative or call 01635 563000.
Merial Animal Health has announced that it has purchased the the anti-inflammatory treatment for lameness in horses, Hyonate® (sodium hyaluronate), from Bayer.
Merial's equine marketing and technical manager, Louise Radford MRCVS said: "Hyonate is an established treatment of lameness in horses due to non-infectious inflammation of joints, using both intra-articular (IA) and intravenous (IV) injection.
"The beneficial effects of HA supplementation are attributable to the anti-inflammatory effects, improvement in viscoelastic properties of the synovial fluid, and interaction with the synovial membrane affecting pain transmission and joint metabolism¹."
For more information telephone Customer Support on 0870 6000123 or contact your local Merial Equine Specialist.
Reference
The company says it thinks the film is an industry first because it depicts veterinary professionals in a way that they have never seen themselves before: cinematically showing the highs and lows of a typical day in veterinary practice.
Vets4Pets also says it wants the film to generate greater recognition for everyone working within the industry, not just its own staff, by showcasing the passion, dedication and commitment that unites them.
Keith Leonard MRCVS, Practice Owner at Vets4Pets Leeds Birstall where some of the video was filmed, said: “While there are no words that can do justice to the sheer passion and determination demonstrated by the entire veterinary community, taking part in this campaign and seeing the result is really emotional.
“After an unimaginably turbulent few years, this campaign makes me feel incredibly proud of my whole team.
"It genuinely shows what it’s like to work in veterinary practice and I can’t thank each and every one of my team enough for their outstanding dedication to the care of our clients – both the pets we care for and their owners.
"We all live and breathe what we do, and I hope they feel a sense of pride when they see this campaign.”
Gordon Dunn, People Director at Vets4Pets, said: “The veterinary sector has experienced immense pressure following years of unprecedented challenges and as an industry we need to do our utmost to ensure that veterinary professionals are supported in their development and careers. But alongside this, we need to understand that recognition goes a long way too.
The clinic is led by Sebastien Behr MRCVS, an RCVS Specialist in Neurology. Patients will benefit from access to the referral centre's MRI scanner and its specialist imaging, anaesthesia and neurology teams.
Dr Behr said: "We are very excited to have launched this specialist clinic. Following detailed consultations with pet owners, the animals will be treated to the very highest level and bespoke care designed for each patient."
The practice is offering a fixed price package for routine diagnostic procedures.
For more information, visit www.willows.uk.net or contact the neurology team on 0121 721 7070.
According to the company, it's the first large-scale EMS online booking system of its type in the veterinary profession and it will mean students can find practice placements at the touch of a button, instead of having to spend time contacting individual surgeries.
With the new system, the 200 CVS practices which currently offer EMS have their own page, where information is provided about the practice, along with a list of available placements.
Once registered, students can search for placements by practice name, location and date.
When a student finds a suitable placement a booking request is triggered, connecting the student to the host practice so that the booking can be confirmed.
CVS has also created a new EMS support framework, based on the RCVS day one competencies, to help practices and students structure each placement.
The company says the new framework puts health, wellbeing and professional skills on a par with clinical skills, to encourage students to take a holistic approach to their development - helping them to grow into happy, competent and confident veterinary surgeons.
Nigel Stansbie, Head of Online Course Creation at CVS, said: “As a major employer within the industry, we are fully committed to supporting the education and development of vet students, by offering high-quality EMS placements, to help them gain the skills and knowledge they will need to thrive when they join the workforce.
“Though we know that there is current debate about the future EMS requirements, we recognise the importance of EMS and are confident that the support we have put in place will enable students to make the most of these valuable work experience opportunties.”
The new CVS EMS online booking system is hosted on the company's knowledge hub: https://www.cvs-knowledgehub.com/.
The Government says that contracts have been secured with Brittany Ferries and DFDS to run ferries into and out of Poole, Portsmouth, Plymouth, Immingham and Felixstowe, thereby relieving pressure on the Dover straights.
Critical goods have been identified as those essential for the preservation of human and animal welfare, including all veterinary medicines authorised under the Veterinary Medicines Regulation 2013, including finished and un-finished products, and Active Pharmaceutical Ingredients (for import and export).
Critical goods also include unauthorised medicines permitted for import under the Veterinary Medicines Directorate’s Special Import Scheme (for import only).
Photo: Shutterstock/Peter Hermes Furian
Amanda Melvin, Senior Product Manager, said: "We’re very excited about this approval as it will allow us to build on the success of our Bravecto chewable tablets for dogs and provide veterinarians and cat owners with another tool in the fight against ticks and fleas. Being able to offer a full 12 week protection means convenience for cat owners and improved compliance rates for veterinarians, so everyone benefits."
Bravecto is applied topically using the new "Twist’n’Use" pipette design which means the cap doesn’t need to be removed.
Full product details are described in the summary of product characteristics (SPC).
For more information, contact your MSD Animal Health representative.
Dechra Veterinary Products has launched a 5 ml bottle of Comfortan (methadone), its titratable analgesia for cats and dogs.
The new sized bottle of Comfortan, designed for use with animals in, or about to experience, moderate to severe pain, is now available from veterinary wholesalers.
Dechra Brand Manager Craig Sankey said: “The new 5ml bottle is a great size for practices which would like to introduce Comfortan into their practice protocols, allowing them to do so in a cost-effective way.
“The availability of a smaller bottle will also be a benefit to practices which due to different surgical needs, currently only use Comfortan in a small number of cases. They will then be able to simply and easily trade up to the 10 ml bottle once they start to use Comfortan on more cases.”
The 5 ml has also been introduced in response to demand from branch practices which had been transferring 10ml bottles between sites and for cat-focused practices which use smaller volumes of the product.
The Care About Cushing’s website is designed to give horse owners the information they need to spot the signs of Cushing's, thereby prompting diagnosis by their veterinary surgeon.
The online resource includes monitoring tools, personalised alerts, owner guides and webinars. It also offers downloadable self-assessment checklists on Cushing’s disease and laminitis to take owners through the signs to look out for.
Owners whose horses have been diagnosed with Cushing’s are encouraged to sign up as a Care About Cushing’s member to keep up-to-date with the latest information about the disease and create a personal profile for their horse in order to monitor progress. One of the membership benefits is an 'ask the expert' section where members can ask questions about Cushing’s disease and laminitis.
The Care About Cushing’s resource supports Boehringer’s ‘Talk About Laminitis’ initiative to raise awareness of the signs of laminitis and its link with Cushing’s disease.
Talk About Laminitis now runs throughout the year and as part of the campaign the laboratory fees for the blood test which detects Cushing’s (the basal ACTH test) are free.
Liz Barrett, equine business head at Boehringer, said: "Our Talk About Laminitis disease awareness initiative has been hugely successful in highlighting the link between laminitis and Cushing’s disease and helping to diagnose Cushing’s. So much so that Cushing’s is now in the top five equine diseases recorded in the UK1."
For further information on Talk About Laminitis or Care About Cushing’s, visit www.talkaboutlaminitis.co.uk, www.careaboutcushings.co.uk or contact your local Boehringer territory manager.
The dog, called Pepe, needed urgent treatment to repair the cornea before it ruptured, so the team at Davies decided to use a new xenograft derived from a pig cornea, rather than waiting to see if an allograft became available.
The xenograft, which was developed in China, is aseptically prepared, sterilised and freeze-dried so it can be stored for months or years if necessary before use.
According to Davies, the graft had been used in China and the USA, where the early results had been promising. Now, following Pepe's successful treatment, Davies is now using the procedure in more cases over here in the UK.
The full case study, with photos, is here: https://www.vetsurgeon.org/veterinary-clinical/small-animal/sa-ophthalmology/m/photo-video-media/138076.aspx
For more information, visit: https://vetspecialists.co.uk/services/ophthalmology/
VetSurgeon member Shailen Jasani MA VetMB MRCVS DipACVECC has launched the Ralph site (theralphsite.com), a website offering support and advice to those coping with pet bereavement.
The site contains forums, downloadable advice sheets, a directory of crematoria and cemeteries, and offers owners the ability to create a memorial for their pet.
The Ralph site was named after Shailen's own cat, which died after a car accident in 2010. Shailen funded the setup of the site, and it is a not-for-proft.
Your tip could be clinical in nature (perhaps specific to a particular discipline, like cardiology or exotics), or to do with practice management, or dealing with clients, or HR, or, well, anything really.
To enter the competition, login to VetSurgeon.org and submit your tip in the forum, here.
Just before you press the button to post your tip, you might like to tick the box marked: "EMAIL ME REPLIES TO THIS POST" which appears immediately above the post button. That way, you'll get an email when someone else posts a tip.
Above each post in the forum, there is now a 'Thank You' link, which allows members to express their thanks for sharing something. The five tips that generate the largest number of 'thank yous' by the end of November will win the Amazon vouchers.
VetSurgeon.org is all about facilitating the sharing of knowledge, ideas and experience. So any tip entered into the competition will also be disseminated, together with the contributor's name, on other social media channels, such as Facebook, Twitter, Linkedin and if you include a photo, on Instagram.
VetSurgeon.org Arlo Guthrie said: "The competition is really designed to show off the new 'thank you' feature on VetSurgeon, which allows members to show their appreciation when someone shares something useful with their peers. In due course, we'll be running similar competitions for the most thanked photos and videos uploaded to our galleries. Watch this space."
Equibactin oral powder comes in a 60g sachet, which Dechra says is the scientifically considered accurate dose1 for two daily treatments for a 600kg horse. The sachets come in a box of 10, which is sufficient for the twice daily treatment of a 600kg horse for five days.
The combination of sulfadiazine and trimethoprim antibiotics (known as TMPS) has a broad spectrum of uses and can be used to treat equine infections associated with Streptococcus and Staphylococcus aureus, gastrointestinal infections associated with E. coli and urogenital infections associated with beta-hemolytic streptococci.
Emma Jennings, Equine and Food Producing Animal Brand Manager, said: “Our product allows for twice daily 30mg/kg treatments, making the treatment of large horses easier and ensuring they receive the correct dose, which is crucial when it comes to tackling antibiotic resistance.”
She added: “TMPS is the only registered oral antibiotic available for use in horses and it is recommended as the first line of treatment for ‘common’ equine bacterial infections including those which have developed through wound infections or open or drained abscesses.2,3
“Effective antibiotics are an important part of the veterinarian’s arsenal when it comes to treating a variety of common bacterial infections in horses. But in recent years, the emergence of drug resistant bacteria has meant that extra precautions must be taken to prevent underdosing - one of the prominent causes of drug resistance.”
Equibactin oral powder is available now in the UK and Ireland. For more information visit www.dechra.co.uk.
References
The Wellington-based hospital is hoping to announce its first resident at the start of next year, who will work under the guidance of Fran Taylor-Brown and Tom Cardy.
This is the first residency programme to be conducted at Cave and has been launched by Fran who, along with Tom, is an EBVS and RCVS specialist in veterinary neurology.
Fran said: "The ECVN accreditation is an important milestone for us as we look to develop and expand our expertise in neurology.
"We are currently undertaking a major recruitment drive and having the capability to offer specialist training in this discipline is another feather in the cap.
"We’re hopeful this approval will open the door to allow clinicians in other disciplines to receive specialist-level training with us in the future."
Cave has also introduced an internship programme to support the growth of the team and has taken on Samantha Gilbert a graduate of James Cook University in Australia.
Bovilis Rotavec Corona is used for the active immunisation of pregnant cows and heifers, 12-3 weeks pre-calving, to raise antibodies against rotavirus, coronavirus and E. coli F5 (K99). Calves gain protection by drinking the fortified colostrum from their vaccinated mothers.
The company says the new license indication will mean greater usage flexibility for UK cattle producers focusing on immunity-led prevention of infectious calf scours.
MSD ruminant veterinary adviser Dr Kat Baxter-Smith said: "On the old license, this vaccine needed to be used within eight hours of opening, so this will be a significant benefit-led change for suckler beef and dairy producers.
"For all-year-round calving dairy herds, for example – that may want to vaccinate successive pregnant dams on different days – it will make an opened bottle of vaccine last much longer. Those running batch calving herds with a long calving period should also benefit. We hope this will help reduce unnecessary wastage of the vaccine on farm and save farmers money.”
MSD says it will still be crucial to store the vaccine properly – upright and refrigerated (at 2-8°C) before and after broaching, and after first use. A broached vial will be able to be used once more during the next 28 days after the first vaccination event and then discarded. Vaccination equipment such as needles and syringes should be sterilized. Use of a multi-dose syringe to minimise vaccine contamination and excessive broaching is recommended.
The vaccine vials should still be shaken well before use. The injection should be made through an area of clean, dry skin with precautions taken against contamination.
The company says the system uses a combination of image recognition technology, algorithms and cloud-based artificial intelligence to deliver accurate testing results at the time of visit, within 9 minutes in fact, giving veterinary surgeons the ability to diagnose and treat patients quickly, without the need for a second appointment.
Vetscan Imagyst will detect the eggs, cysts, and oocysts of whipworm, hookworm, roundworm, Giardia, and coccidia
Richard Goldstein, DVM, DACVIM, DECVIM-CA, VP Global Diagnostics Medical Affairs at Zoetis, said: "Parasites are a threat throughout the year, making routine monitoring critical to pet health.
“With Vetscan Imagyst, the ability to have accurate, fast results at the point-of-care empowers veterinarians to diagnose and treat in the same visit, increasing compliance and eliminating follow-up appointments and call backs, thus enhancing the overall pet owner experience.”
Vetscan Imagyst will launch in the UK next week. For more information, contact your Zoetis representative or visit at www.vetscanimagyst.com.
Zenifel contains synthetic feline facial pheromones which imitate the facial F3 pheromone which has been found to be significantly important when it comes to cats creating areas they feel safe and relaxed in1.
According to the company, Zenifel contains a 48ml vial of the same synthetic F3 feline facial pheromone as the market leader, but, thanks to its own diffusion system and a higher concentration of F3, lasts up to 6 weeks; i.e. 50% longer. This, says Virbac, means that Zenifel is both more economical and more environmentally friendly.
Alongside the launch of the new product, Virbac is offering a practice support pack which includes things you need to create a calm area for feline visitors and promote the benefits of pheromones to pet owners. The company is also running a promotion in which practices could be eligible for a year’s free supply of Zenifel.
For more information, contact your local Virbac Territory Manager.
The procedure has already been performed in the US and Germany, where it is reported to have had a success rate of 70-80% in around 250 cases, many of which were show jumpers, eventers and dressage horses.
The team at Liphook, led by European Specialist Rachel Tucker (pictured), has now performed the procedure on six horses.
Rachel said: “Enlargement of the articular process joints of the lower neck is a relatively common finding in horses, but occasionally this can cause compression and irritation of the spinal nerves.
"The foraminotomy procedure means horses experiencing nerve pain can be made comfortable and have a good chance of returning to ridden work and a competition career.
“The surgery is minimally invasive but it is a very delicate procedure to perform because you are working very close to the spinal cord.
"Due to the location, the surgery is performed down a single portal under direct visualisation using a camera, guided by ultrasound and X-ray.
"What has been remarkable so far has been the rapid recovery of the horses, who have been home and out in a small paddock within a few days of surgery with some showing rapid signs of improved comfort and movement.
“We are very pleased with how the procedures at Liphook went.
"Our patients are continuing to recover well and we are looking forward to following their progress in the future.
https://liphookequinehospital.co.uk
In the study titled “Safety of early postoperative hydrotherapy in dogs undergoing thoracolumbar hemilaminectomy”, the medical records of a single referral hospital in Sweden were retrospectively reviewed to identify dogs that had been treated with hemilaminectomy for acute or chronic thoracolumbar IVDE and had commenced hydrotherapy within five days after surgery.
Information collected from the medical records included signalment, presenting clinical signs, severity of neurological signs, initiation and duration of hydrotherapy, postoperative complications and follow-up.
Postoperative complications were considered major if there was a need for hospitalisation, surgery or if the dog died or was euthanised as a direct consequence of the complication.
A complication was deemed minor if outpatient medical treatment was sufficient to rectify it.
A total of 83 dogs were included in the study.
Hydrotherapy was started within a mean of 2.7 (one to five) days after surgery and consisted of swimming without underwater treadmill (UWTM) in dogs with severe paraparesis or paraplegia.
With neurological improvement, and when supported ambulation was possible, UWTM was initiated.
Ninety-six percent of the dogs used swimming as postoperative hydrotherapy, starting with a mean of 2.7 days after surgery, fifty-seven percent of the dogs used UWTM as the postoperative hydrotherapy, starting with a mean of 13 days after surgery.
Forty-five percent of dogs used both hydrotherapeutic modalities.
Dr Abtin Morjarradi, corresponding author for the paper, said: “A total of 10 minor complications were recorded during the study period, including surgical site infection (SSI) (n=5), diarrhoea (n=4) and urinary tract infection (n=1).
Major complications were recorded in 26 dogs during the study period and included euthanasia (n=13), acute dermatitis (n=1), spinal abscess (n=1) and disc extrusion (n=1).
Reasons for euthanasia were urinary incontinence (n=5), lack of neurological improvement (n=2), clinical suspicion of progressive myelomalacia (PMM) (n=2), persistent pain (n=1), aggression (n=1) and widespread cellulitis with an abscess caudal to the right stifle without known cause (n=1).”
Abtin added: “Follow-up visits for 71 dogs were performed at a mean of 15.3 (9 to 30) days, and 68 dogs at a mean of 45.9 (30 to 111) days, after surgery.
"At the first follow-up visit 68% of the dogs were ambulatory with Modified Frankel Score (MFS) 4 or higher.
"At the last follow-up visit 97% of the dogs were ambulatory with MFS 4 or higher, with 34% demonstrating normal neurological function. None of these dogs deteriorated after the initiation time of hydrotherapy.”
Nicola Di Girolamo, Editor of JSAP, said: “Whilst previous studies indicate that early rehabilitation may be beneficial after acute spinal cord injury, the optimal timing to start hydrotherapy is unclear.
“Despite a high number of complications being recorded in the present study, it is not clear how many of these complications were directly related to the initiation time of hydrotherapy and therefore further research is required.”
The full article can be found in the December issue of the Journal of Small Animal Practice: https://onlinelibrary.wiley.com/doi/full/10.1111/jsap.13412.
Dr Bohnen faced two charges. The first was that in March 2017, she failed to attend to Belle, a Cavalier King Charles Spaniel, in order to provide appropriate and adequate care including: assisting Belle with urination, monitoring her with a view to considering alternative treatment options, and monitoring her with a view to providing her owners with an update on her condition.
The second charge was that Dr Bohnen later claimed dishonestly that she had attended to the animal, both to the owners, in clinical records hospital records, in a note provided to colleagues and during internal disciplinary proceedings held at her practice.
At the outset of the hearing the Committee considered an application from Dr Bohnen for the hearing to be postponed as she was now based in her home country of South Africa, and said she could not apply for a visa to return to the UK until later in the year and internet access in her location was poor.
However, the Committee found that the RCVS had properly served the notice of inquiry to Dr Bohnen in accordance with the current rules, that she had had sufficient time and opportunity to apply for a visa since receiving the notice and that, in any case, she could remotely ‘attend’ the hearing via Skype or telephone if necessary by travelling to somewhere that did have adequate internet connectivity, and so it refused the application.
The Disciplinary Committee then considered the facts of the case and heard evidence from the owners of Belle, the clinical director of the practice that Dr Bohnen worked in at the relevant time and a veterinary nurse, who was a student doing her training at the practice during the time of the events in question.
Having considered all of the evidence, the Committee dismissed the parts of the first charge relating to considering alternative treatment options and updating the owners in relation to Belle’s condition. They did, however, find the charge proven in relation to Dr Bohnen failing to assist Belle with urination.
The Committee found all aspects of the second charge proven in its entirety after Dr Bohnen admitted in advance of the hearing, that her representations were false and misleading.
The Committee then went on to consider whether the second charge and the aspects of the first charge that were found proven amounted to serious professional misconduct both individually and cumulatively.
The Committee considered that Dr Bohnen’s conduct in failing to assist Belle with urination, whilst falling below the standard to be expected of a reasonably competent veterinary surgeon, did not amount to serious professional misconduct.
The Committee did however find that Dr Bohnen’s conduct with regards to the second charge constituted serious professional misconduct.
Professor Alistair Barr, chairing the Committee and speaking on its behalf, said: "The Committee considers that the respondent’s dishonesty was the prime aggravating factor in this case. Although overall it could be regarded as a single incident, the Committee has found that it involved the fabrication of a number of notes and clinical records in the immediate aftermath of the death of the dog, but, thereafter, the respondent continued to deny the falsity of the fabricated records that she had created up to and until the conclusion of her interview by the practice on 30 March 2017.
"During that time, the respondent had contacted the alarm company responsible for the security of the premises of the practice, to enquire whether the security system would record the times of the alarm being switched on and off. This indicated that the respondent’s dishonesty continued over a significant period of time, and that her persistence in sticking to her story became premeditated. In other words, the respondent’s conduct over this time indicated a clear attempt to deceive."
Regarding the sanction for Dr Bohnen, the Committee considered that the principle aggravating factors in the case were serious dishonesty towards both her colleagues and the owners of the dog and involved clear breaches of the Code of Professional Conduct. By way of mitigation, the Committee noted that Dr Bohnen is of previous good character with no other professional findings against her and that she had demonstrated some insight into her behaviour and had admitted being dishonest and misleading prior to the hearing.
Summing up, Professor Barr said: "Because of the seriousness of this case, the Committee did not consider that it was appropriate to postpone judgement, take no further action, or to administer a reprimand and warning as to future conduct. The Committee considered that the respondent’s conduct, involving significant and admitted dishonesty over a period of time, required a significant penalty, in order to protect the welfare of animals and to serve the public interest.
"Accordingly, the Committee has decided to direct that the respondent’s registration be suspended for a period of nine months."
Dr Bohnen has 28 days from being informed of the Committee’s decision to lodge an appeal with the Privy Council.
Whilst you're here, take a moment to see our latest job opportunities for vets.
Genitrix has reformulated and repackaged its Lacto B range of broad spectrum probiotic supplements for the maintenance of normal digestive function in pets.
The products are provided in a powder formulation for direct application onto food or to be dissolved in water. They are available in five-day sachets or in 75g tubs suitable for longer term use.
Genitrix says that unlike single-strain formulations, the Lacto B range contains live freeze-dried cultures of three probiotic organisms which, when ingested, colonise the gut, helping to re-establish normal function. The three strains of probiotic organisms occupy the same sites in the gut as certain pathogenic bacteria thus preventing their attachment.
Indicated for dogs, cats, rabbits, rodents, reptiles and birds, the Lacto range is formulated to provide a guaranteed concentration of 1x109 CFU/g probiotic organisms.
Genitrix suggests that the Lacto B range can be particularly helpful in:
Rob Watkins, Marketing Director at Genitrix, said: "The Lacto range has been tried and trusted in small animal practice for twelve years and feedback shows that its multi-species indication make it a flexible and cost-effective solution."
"With its new formulation and new packaging, we believe it will prove even more attractive as a high potency probiotic supplement."
For more information, please click here.
Merial Animal Health has launched Certifect, a new POM flea and tick treatment for dogs.
The product was launched at a series of presentations by the survival and bushcraft expert, Ray Mears (pictured right) last week.
The connection between Ray Mears and a new flea and tick treatment for domestic dogs became clear as he recounted his experience of contracting Lyme Disease in the UK. Indeed, by the time he'd finished describing the crippling pain he'd suffered and the industrial quantities of morphine and tramadol he'd needed, most vets in the room were probably ready to place an order for a tonne of the new product.
But to dismiss it as just a polished marketing exercise would be wrong. According to the Health Protection Agency, cases of Lyme disease in people have risen from 296 in 2001 to 953 in 2010. It is thought that because the disease is difficult to diagnose, it is likely to be significantly under-reported. In addition, a study by Faith Smith from the University of Bristol last year found that of 3534 dogs examined, 810 (22.9%) were carrying at least one tick.
So, what about the new product? Well, it's essentially Frontline Combo (fipronil + the insect growth regulator, S-methoprine) but with added amitraz. At the low dose contained in Certifect, Merial explained that amitraz doesn't demonstrate acaricidal properties itself, but instead potentiates the effect of the fipronil and causes ticks to detach or fail to attach. It also causes ticks to move around more than they do normally, thereby exposing them to more fipronil.
Merial says the acaricidal effect of Certifect can be seen two hours after application, and that more than 90% of ticks are eliminated within 24 hours. After treatment, Certifect prevented 94.5% to 100% of ticks attaching until day 29, thereby reducing the risk of disease transmission. In terms of integrated flea control, think Frontline Combo.
Certifect can be used on pregnant and lactating bitches, on puppies from 8 weeks weighing more than 2kg, and on dogs which live in households with cats.
The re-categorisation means veterinary practices can sell the topical parasiticides to ‘walk-in clients’ without the need of a prescription.
Andrew Fullerton, veterinary surgeon and product manager at Ceva Animal Health, said: “The new NFA-VPS category for Vectra 3D spot-on solution for dogs and Vectra Felis 423mg/42.3mg spot-on solution for cats provides veterinary practices with greater flexibility to sell easy-to-use, fast and effective parasite prevention and treatment without a prescription."
For more information, contact your Ceva Animal Health account manager or email cevauk@ceva.com.
The company says this means that using Solacyl as an alternative to antibiotics could reduce overall antibiotic use by 4.4 tonnes a year.
The research was carried out by dairy veterinary consultant Owen Atkinson BVSc DHCP MRCVS, an RCVS recognised specialist in cattle health and production, at three English calf rearing units between November 2017 and May 2018. It involved four groups of beef calves from different dairy farms.
The 258 calves were given Solacyl (sodium salicylate) in-feed on the five days immediately upon arrival at the units (a high-risk period for animals to contract bovine respiratory disease).
According to Dechra, the use of Solacyl resulted in a reduction in antibiotic use of between 16% and 73% (based on doses), depending on the farm. Across all groups, the reduction was 43%.
Dechra says that neither the health of the calves nor the profitability of the rearing operations were compromised.
Owen Atkinson said: "I was involved in analysing the data and the data showed that there was no significant difference in growth rates or in mortality or in days to reach a target weight in the calves that had Solacyl, compared to previous batches of calves that had followed a prophylactic antibiotic protocol.
"I think this is an ideal protocol for those farmers who are competent, who are able to spot early pneumonia symptoms and are prepared to perhaps treat a slightly higher proportion of calves than they would otherwise have treated. They can now do that with higher confidence that their results should be as good as if they had used prophylactic antibiotics."
Dechra Farm Animal Veterinary Adviser Alana McGlade BVmedsci (hons) BVM BVS MRCVS added: "Sodium salicylate has the same fever-controlling, pain-managing and inflammation-reducing benefits in livestock as aspirin can have in humans.
"It can be administered conveniently to groups of animals, which means it can be given prior to known stress points in animals’ lives. This can be continued through and after those events, providing a welfare benefit and reducing the risk of a loss of appetite and its resulting effects.
"Solacyl can be administered without the supervision of a vet and that makes it a cost-effective and practical solution for farmers that can lead to a notable reduction in routine antibiotic use whilst protecting the welfare of a herd."
Dechra has now published a white paper which you can download here: "Enhancing welfare and combating antimicrobial resistance while maintaining productivity on calf units".
The results of the research will be presented at the BCVA Congress in October 2018.